特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况 1、会议召开时间 1）现场会议时间：2026年1月28日下午14:00。 登录新浪财经APP 搜索【信披】查看更多考评等级 2）网络投票时间：通过深圳证券交易所交易系统进行投票的时间为2026年1月28日上午9:15-9:25，9:30- 11:30，下午13:00-15:00；通过深圳证券交易所互联网系统进行投票的时间为2026年1月28日上午9:15至 下午15:00期间的任意时间。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 会议的召集、召开及表决程序符合《公司法》等相关法律法规及部门规章和《公司章程》等有关规定。 二、会议出席情况 2、会议召开地点：浙江省台州市温岭市城东街道百丈北路28号，公司行政楼会议室。 3、会议召集人：万邦德医药控股集团股份有限公司（以下简称"公司"）董事会 4、会议主持人：董事长赵守明先生。 1.出席本次股东会的股东或股东代理人共计184人，代表有表决权的股份数312,636,981股，占公司有表 决权总股 ...

Core Viewpoint - Haisheng Pharmaceutical (002099.SZ) has signed an "Innovative Drug Cooperation Agreement" with Wanbangde Pharmaceutical Holdings Group Co., Ltd., focusing on collaboration for the treatment of amyotrophic lateral sclerosis (ALS) [1] Group 1 - The initial collaboration will concentrate on the development and commercialization of the orphan drug WP205, which has already received orphan drug designation from regulatory authorities [1] - Future cooperation will also include the development of small molecule cyclic peptide agonists targeting melanocortin receptors (MCR) [1]

Group 1 - The core viewpoint of the news is that Wanbangde's stock has experienced fluctuations, with a recent decline of 2.07% and a total market value of 8.405 billion yuan [1] - As of January 7, the stock price is reported at 13.74 yuan per share, with a trading volume of 65.4153 million yuan and a turnover rate of 0.85% [1] - The company has seen a net outflow of main funds amounting to 8.6265 million yuan, with significant selling pressure from large orders [1] Group 2 - For the year-to-date, Wanbangde's stock has decreased by 1.36%, but has increased by 10.18% over the past 20 days [1] - The company reported a revenue of 1.018 billion yuan for the first nine months of 2025, reflecting a year-on-year decrease of 5.28%, and a net profit of 4.4678 million yuan, down 90.22% year-on-year [2] - The company has distributed a total of 613 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [3] Group 3 - Wanbangde's main business segments include medical devices (41.63% of revenue), chemical raw materials and preparations (24.69%), other goods (19.61%), and traditional Chinese medicine (14.07%) [1] - The company is classified under the pharmaceutical and biotechnology sector, specifically in traditional Chinese medicine [1] - As of September 30, the number of shareholders decreased by 32.75% to 26,400, while the average number of circulating shares per person increased by 48.70% to 20,944 shares [2]

Group 1 - The core viewpoint of the news is that Wanbangde's stock has experienced significant fluctuations, with a year-to-date increase of 107.62% but a recent decline of 9.25% over the last five trading days [1] - As of November 19, Wanbangde's stock price was reported at 13.35 yuan per share, with a total market capitalization of 8.166 billion yuan [1] - The company has seen a net inflow of main funds amounting to 503,000 yuan, with large orders showing a mixed buying and selling trend [1] Group 2 - Wanbangde Medical Holdings Group Co., Ltd. was established on March 31, 1999, and listed on November 20, 2006, with its main business involving the production and sales of aluminum processing products and medical devices [2] - The revenue composition of Wanbangde includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [2] - As of September 30, the number of shareholders decreased by 32.75% to 26,400, while the average circulating shares per person increased by 48.70% to 20,944 shares [2] Group 3 - Wanbangde has distributed a total of 613 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the news is that Wanbangde's stock has experienced fluctuations, with a year-to-date increase of 124.11% but a recent decline in the last five and twenty trading days [1][2] - As of November 13, Wanbangde's stock price was 14.41 yuan per share, with a market capitalization of 8.814 billion yuan [1] - The company has seen a net outflow of 503,500 yuan in principal funds, with significant buying and selling activity on the stock [1] Group 2 - Wanbangde's main business segments include medical devices (41.63% of revenue), chemical raw materials and preparations (24.69%), other goods (19.61%), and traditional Chinese medicine (14.07%) [1] - For the period from January to September 2025, Wanbangde reported operating revenue of 1.018 billion yuan, a year-on-year decrease of 5.28%, and a net profit attributable to shareholders of 4.4678 million yuan, down 90.22% year-on-year [2] - The company has a total of 26,400 shareholders as of September 30, with a decrease of 32.75% from the previous period, and an increase of 48.70% in average circulating shares per shareholder [2] Group 3 - Since its A-share listing, Wanbangde has distributed a total of 613 million yuan in dividends, with 122 million yuan distributed over the past three years [3]

Core Viewpoint - Wanbangde's stock price has shown significant growth this year, with a year-to-date increase of 130.48%, despite a recent decline in revenue and net profit [1][2]. Group 1: Stock Performance - As of November 12, Wanbangde's stock price rose by 2.07% to 14.82 CNY per share, with a total market capitalization of 9.065 billion CNY [1]. - The stock has experienced a trading volume of 74.29982 million CNY, with a turnover rate of 0.91% [1]. - Year-to-date, the stock has been on the leaderboard seven times, with the most recent net purchase of 6.4273 million CNY on October 13 [1]. Group 2: Financial Performance - For the period from January to September 2025, Wanbangde reported a revenue of 1.018 billion CNY, a year-on-year decrease of 5.28% [2]. - The net profit attributable to shareholders was 4.4678 million CNY, reflecting a significant decline of 90.22% year-on-year [2]. - The company has distributed a total of 613 million CNY in dividends since its A-share listing, with 122 million CNY distributed over the past three years [2]. Group 3: Business Overview - Wanbangde, established on March 31, 1999, and listed on November 20, 2006, operates in the production and sales of aluminum processing products and medical devices [2]. - The company's revenue composition includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [2]. - Wanbangde is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine, and is associated with various concept sectors including non-ferrous aluminum and pharmaceutical e-commerce [2].

Core Insights - Wanbangde's stock price increased by 2.51% on October 28, reaching 15.54 CNY per share, with a total market capitalization of 9.506 billion CNY [1] - The company has seen a year-to-date stock price increase of 141.68%, with a recent decline of 0.70% over the last five trading days [1] Financial Performance - For the first half of 2025, Wanbangde reported a revenue of 579 million CNY, a year-on-year decrease of 23.15%, and a net profit attributable to shareholders of 13.4635 million CNY, down 64.29% year-on-year [2] - The company has distributed a total of 613 million CNY in dividends since its A-share listing, with 122 million CNY distributed over the last three years [2] Shareholder Information - As of June 30, Wanbangde had 39,300 shareholders, an increase of 42.08% from the previous period, with an average of 14,085 circulating shares per shareholder, a decrease of 30.25% [2] Business Overview - Wanbangde, established on March 31, 1999, and listed on November 20, 2006, is primarily engaged in the production and sales of aluminum processing products, medical devices, and the research, production, and sales of modern Chinese medicine, chemical raw materials, and chemical preparations [1] - The revenue composition of Wanbangde includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [1] Market Activity - The company has appeared on the trading leaderboard seven times this year, with the most recent instance on October 13, where it recorded a net purchase of 6.4273 million CNY [1] - The net inflow of main funds on October 28 was 1.1317 million CNY, with large orders accounting for 21.37% of total purchases [1]

Group 1 - The core viewpoint of the news is that Wanbangde's stock has shown significant growth this year, with a year-to-date increase of 143.55% and notable recent trading activity [1] - As of October 21, Wanbangde's stock price reached 15.66 yuan per share, with a total market capitalization of 9.579 billion yuan [1] - The company has experienced a net outflow of main funds amounting to 2.4709 million yuan, with large orders showing mixed buying and selling activity [1] Group 2 - Wanbangde Pharmaceutical Holdings Group Co., Ltd. was established on March 31, 1999, and went public on November 20, 2006, focusing on the production and sales of aluminum processing products and medical devices [2] - The company's main business revenue composition includes medical devices (41.63%), chemical raw materials and preparations (24.69%), other goods (19.61%), and traditional Chinese medicine (14.07%) [2] - For the first half of 2025, Wanbangde reported operating revenue of 579 million yuan, a year-on-year decrease of 23.15%, and a net profit attributable to shareholders of 13.4635 million yuan, down 64.29% year-on-year [2]

Core Viewpoint - Wanbangde's stock has shown significant growth this year, with a year-to-date increase of 137.17%, indicating strong market performance and investor interest [1][2]. Group 1: Stock Performance - As of October 16, Wanbangde's stock price reached 15.25 CNY per share, with a trading volume of 93.9752 million CNY and a turnover rate of 1.14%, resulting in a total market capitalization of 9.328 billion CNY [1]. - The stock has experienced a 24.90% increase over the last five trading days, a 57.22% increase over the last 20 days, and a 77.95% increase over the last 60 days [1]. - Wanbangde has appeared on the trading leaderboard seven times this year, with the most recent appearance on October 13, where it recorded a net buy of 6.4273 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Wanbangde reported a revenue of 579 million CNY, reflecting a year-on-year decrease of 23.15%, while the net profit attributable to shareholders was 13.4635 million CNY, down 64.29% year-on-year [2]. - The company has distributed a total of 613 million CNY in dividends since its A-share listing, with 122 million CNY distributed over the past three years [3]. Group 3: Business Overview - Wanbangde, established on March 31, 1999, and listed on November 20, 2006, is based in Taizhou, Zhejiang Province, and operates in the production and sales of aluminum processing products, medical devices, and the research and production of traditional Chinese medicine and chemical raw materials [2]. - The company's revenue composition includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [2]. - Wanbangde is categorized under the pharmaceutical and biotechnology industry, specifically in traditional Chinese medicine, and is associated with concepts such as the Belt and Road Initiative, non-ferrous aluminum, share buybacks, small-cap stocks, and medical devices [2].

Core Viewpoint - Wanbangde's stock price has shown significant volatility, with a year-to-date increase of 71.38% but a recent decline of 4.09% over the last five trading days [2] Group 1: Stock Performance - As of September 25, Wanbangde's stock price was 11.02 CNY per share, with a market capitalization of 6.741 billion CNY [1] - The stock has experienced a 17.36% increase over the past 20 days and a 57.65% increase over the past 60 days [2] - The company has appeared on the "龙虎榜" (top trading list) five times this year, with the most recent occurrence on August 27 [2] Group 2: Financial Performance - For the first half of 2025, Wanbangde reported revenue of 579 million CNY, a year-on-year decrease of 23.15%, and a net profit attributable to shareholders of 13.4635 million CNY, down 64.29% year-on-year [2] - The company's main business revenue composition includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [2] Group 3: Shareholder Information - As of June 30, the number of shareholders for Wanbangde was 39,300, an increase of 42.08% from the previous period, while the average circulating shares per person decreased by 30.25% to 14,085 shares [2] Group 4: Dividend Information - Since its A-share listing, Wanbangde has distributed a total of 613 million CNY in dividends, with 122 million CNY distributed over the past three years [3]